Enhancing the solubility and antibacterial activity of novel molecular salts of enrofloxacin drug with isomeric pyridinedicarboxylic acids.

Valeryia Hushcha, Anna Ben, Aleksandra Felczak, Katarzyna Lisowska, Zdzisław Kinart, Michał Gacki, Lilianna Chęcińska

Abstract read

In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Veterinary world · 2025
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Valeryia HushchaFaculty of Chemistry, University of Lodz, Pomorska 163/165, 90-236, Lodz, Poland.

Anna BenFaculty of Chemistry, University of Lodz, Pomorska 163/165, 90-236, Lodz, Poland.

Aleksandra FelczakFaculty of Biology and Environmental Protection, University of Lodz, Banacha 12/16, 90-237, Lodz, Poland. aleksandra.felczak@biol.uni.lodz.pl.

Katarzyna LisowskaFaculty of Biology and Environmental Protection, University of Lodz, Banacha 12/16, 90-237, Lodz, Poland.

Zdzisław KinartFaculty of Chemistry, University of Lodz, Pomorska 163/165, 90-236, Lodz, Poland.

Michał GackiInstitute of General and Ecological Chemistry, Faculty of Chemistry, Lodz University of Technology, Żeromskiego 116, 90-924, Lodz, Poland.

Lilianna ChęcińskaFaculty of Chemistry, University of Lodz, Pomorska 163/165, 90-236, Lodz, Poland. lilianna.checinska@chemia.uni.lodz.pl.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Enrofloxacin (EFX) is a third-generation synthetic fluoroquinolone with a broad spectrum of antibacterial activity but suffers from low water solubility, affecting its bioavailability. This study attempts to enhance the physicochemical and biological properties of enrofloxacin by converting it into multicomponent forms using crystal engineering concepts. Cocrystallization of enrofloxacin with isomeric pyridine-2,n-dicarboxylic acids (n = 3,4,5,6) resulted in four new crystalline salts (1:1): EFX·Py2,3DCA, EFX·Py2,4DCA, EFX·Py2,5DCA·H

Indexed as

Anti-Bacterial AgentsEnrofloxacinMicrobial Sensitivity TestsSolubilityCarboxylic AcidsCrystallizationCrystallography, X-RayDicarboxylic AcidsGram-Negative BacteriaPyridinesSaltsSpectroscopy, Fourier Transform InfraredAnti-Bacterial AgentsCarboxylic AcidsDicarboxylic AcidsEnrofloxacinPyridinesSaltsAntibacterial activityCrystal engineeringCrystal structureEnrofloxacinFluoroquinolonesSolubility

Identifiers

PMID39592802

DOI10.1038/s41598-024-80665-y

PMCPMC11599901

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.